Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVAX
stocks logo

NVAX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
91.00M
-78.1%
0.150
-84.85%
128.00M
+51.46%
-0.475
-37.5%
127.00M
+43.81%
-0.345
-33.65%
Estimates Revision
The market is revising Downward the revenue expectations for Novavax, Inc. (NVAX) for FY2025, with the revenue forecasts being adjusted by -6.82% over the past three months. During the same period, the stock price has changed by -16.64%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.82%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-173.93%
In Past 3 Month
Stock Price
Go Down
down Image
-16.64%
In Past 3 Month
4 Analyst Rating
up Image0
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 7.00 USD and a high forecast of 19.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
1 Sell
Hold
up Image0
Current: 6.410
sliders
Low
7.00
Averages
11.25
High
19.00
up Image0
Current: 6.410
sliders
Low
7.00
Averages
11.25
High
19.00
JPMorgan
Underweight
downgrade
$9 -> $7
2025-05-09
Reason
JPMorgan
Price Target
$9 -> $7
2025-05-09
downgrade
Underweight
Reason
JPMorgan lowered the firm's price target on Novavax to $7 from $9 and keeps an Underweight rating on the shares. The company's Q2 beat was driven by the accelerated recognition of deferred revenue, the analyst tells investors in a research note. However, the firm sees the "saga" surrounding the application for Novavax's COVID-19 vaccine dominating investor attention given eligible milestones from partner Sanofi. JPMorgan expects the shares to re-rate down on the "increasingly onerous vaccine regulatory environment."
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2024-12-10
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2024-12-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2024-11-13
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2024-11-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$19
2024-11-12
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$19
2024-11-12
Reiterates
Strong Buy
Reason
Jefferies
Roger Song
Strong Buy
Maintains
$31 → $25
2024-10-16
Reason
Jefferies
Roger Song
Price Target
$31 → $25
2024-10-16
Maintains
Strong Buy
Reason
B. Riley Securities
Mayank Mamtani
Strong Buy
Reiterates
$23 → $26
2024-10-10
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$23 → $26
2024-10-10
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novavax Inc (NVAX.O) is -10.01, compared to its 5-year average forward P/E of 1.06. For a more detailed relative valuation and DCF analysis to assess Novavax Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
1.06
Current PE
-10.01
Overvalued PE
24.78
Undervalued PE
-22.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.19
Current EV/EBITDA
1.62
Overvalued EV/EBITDA
48.95
Undervalued EV/EBITDA
-75.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.46
Current PS
2.26
Overvalued PS
4.59
Undervalued PS
0.33

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 218.5% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

NVAX News & Events

Events Timeline

(ET)
2025-06-18
11:06:20
Kennedy considers review of aluminum in vaccines, Bloomberg says
select
2025-06-12 (ET)
2025-06-12
06:00:36
RFK Jr. names eight members to vaccine panel, WSJ reports
select
link
2025-06-11 (ET)
2025-06-11
15:16:26
Novavax CIC data 'unremarkable,' as hoped, says BTIG
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
06-17SeekingAlpha
Novavax slips as Citi launches with Sell rating on pipeline concerns

  • Citi's Recommendation: Novavax shares dropped after Citi initiated coverage with a Sell rating and a $6 price target, citing concerns over the company's focus on respiratory vaccines amidst declining immunization rates and strong competition.

  • Market Sentiment: Despite Citi's negative outlook, Wall Street analysts maintain an average Buy rating for Novavax, while Seeking Alpha authors and their Quant System suggest holding the stock.

Preview
4.0
06-17Benzinga
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

  • Analyst Ratings Updates: Several Wall Street analysts have initiated coverage on various companies, with notable ratings including a Buy for Artivion, Inc. (AORT) with a price target of $35, and a Sell for Novavax, Inc. (NVAX) with a price target of $6.

  • Stock Performance Insights: Coinbase Global, Inc. (COIN) received a Buy rating with a price target of $353.3, while Theravance Biopharma, Inc. (TBPH) and Venture Global, Inc. (VG) also received Buy ratings with targets of $24 and $20 respectively.

Preview
8.5
06-12Benzinga
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

  • BioNTech Acquires CureVac: BioNTech SE has agreed to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, allowing CureVac shareholders to exchange their shares for BioNTech ADSs. The deal aims to enhance BioNTech's capabilities in mRNA-based cancer immunotherapy and is expected to close in 2025.

  • Financial Developments: BioNTech recently entered a co-development agreement with Bristol Myers Squibb worth up to $10.1 billion, while CureVac's patent validity was upheld by the European Patent Office despite challenges from BioNTech.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novavax Inc (NVAX) stock price today?

The current price of NVAX is 6.41 USD — it has increased 1.75 % in the last trading day.

arrow icon

What is Novavax Inc (NVAX)'s business?

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

arrow icon

What is the price predicton of NVAX Stock?

Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 7.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novavax Inc (NVAX)'s revenue for the last quarter?

Novavax Inc revenue for the last quarter amounts to 666.66M USD, increased 610.30 % YoY.

arrow icon

What is Novavax Inc (NVAX)'s earnings per share (EPS) for the last quarter?

Novavax Inc. EPS for the last quarter amounts to 2.93 USD, decreased -379.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novavax Inc (NVAX)'s fundamentals?

The market is revising Downward the revenue expectations for Novavax, Inc. (NVAX) for FY2025, with the revenue forecasts being adjusted by -6.82% over the past three months. During the same period, the stock price has changed by -16.64%.
arrow icon

How many employees does Novavax Inc (NVAX). have?

Novavax Inc (NVAX) has 952 emplpoyees as of June 23 2025.

arrow icon

What is Novavax Inc (NVAX) market cap?

Today NVAX has the market capitalization of 1.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free